Case Study

Delivering Strategic Biostatistics Support to Enable Phase 2b Funding Decisions

A small pharmaceutical company needed Phase 2b analysis and reporting to secure additional venture capital funding, but budget constraints halted the study and its CRO disengaged. With only months remaining to meet investor deadlines, MMS was engaged to provide targeted biostatistical and reporting support. MMS prioritized decision-critical analyses within limited budget and time, enabling completion of key outputs needed for investor discussions and funding decisions.

The Challenge

Budget Constraints Stall Phase 2b Progress

During Phase 2b development, the sponsor faced budget constraints that led to early study discontinuation, leaving planned analyses incomplete. The existing clinical research partner withdrew support without additional funding. Despite this, the sponsor still required high-quality data outputs for investor discussions. With limited time and budget, a pragmatic, cost-conscious approach was needed to deliver credible, decision-relevant analyses while maintaining analytical rigor.

The Solution

Disciplined Prioritization of High-Impact Analyses

MMS assessed the remaining study scope and prioritized deliverables to align with the sponsor's limited budget and investor needs. Instead of completing all planned outputs, the team focused on the most critical analyses and tables needed for key scientific and investment questions. MMS prepared essential data displays and concise statistical reports, ensuring data integrity while minimizing unnecessary work. After study completion, MMS also provided additional biostatistical insights to support stronger messaging for review discussions.

The Results

Phase 2b Study Completed and Funding Secured

By applying a disciplined, value-focused approach, MMS completed the Phase 2b analyses on time and within the remaining budget. The sponsor used the resulting data and reports to secure venture capital funding, supporting continued operations and future development. The engagement highlighted how targeted biostatistical prioritization can enable critical decision-making and deliver business value even under severe financial constraints.

"MMS stepped in and immediately prioritized the project deliverables to maximize cost savings."

– Sr. Associate, Global Safety, Large Biotech

Key Success Factors

- Strategic prioritization of analyses to focus on the most decision-critical outputs
- Ability to work effectively within tight budget and timeline constraints
- Disciplined data cleaning and reporting to reduce unnecessary effort
- Delivery of concise, investor-ready statistical outputs
- Biostatistical expertise applied in a pragmatic, business-aware manner

Let's talk!

If you'd like to discuss this case study further or learn more on how our technology enabled services can support your development project, please visit **mmsholdings.com** or get in touch **info@mmsholdings.com**